Disc Medicine, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Disc Medicine reported Q2 2026 net loss of $59.5M (vs. $55.2M YoY) with cash/equivalents/securities of $717.7M (funding into 2029). Key milestones: FDA Type A meeting on bitopertin aligned Phase 3 APOLLO study (N=183, topline Q4 2026) can support CRL response; selcodebart showed 56% major anemia response in RALLY-MF myelofibrosis trial; DISC-3405 fully enrolled RESTORE-PV study (data Q3 2026) and progressing Phase 1b sickle cell (data Q4 2026). EAP launched for bitopertin in EPP.
Why this rating
Multiple near-term Phase 3/2b readouts could validate pipeline; $718M cash strong for $1.4B market cap; FDA alignment de-risks bitopertin pathway, but still pre-approval stage.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.